VTV Therapeutics (NASDAQ:VTVT)

CAPS Rating: 1 out of 5

Caps

How do you think VTVT will perform against the market?

Add Stock to CAPS Watchlist

All Players

3 Outperform
11 Underperform
 

All-Star Players

1 Outperform
10 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top VTVT Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

TSIF (99.97)
Submitted April 18, 2018

Lead drug stopped. Has others in pipe, but bleeding $4 to $6M a quarter and cash position dwindling with high AP. Highly compensated leadership.Two phase II for Diabetes will require partnership and funding.Over $150M net negative.The $10M from sale… More

VTVT VS S&P 500 (SPY)

VTVT Summary

Recent Community Commentary

Read the most recent pitches from players about VTVT.

Recs

0
Member Avatar SmartAce (99.96) Submitted: 4/19/2018 1:00:24 PM : Underperform Start Price: $2.09 VTVT Score: +23.71

Writing cuss words on the white space of textbook pages is marginally offensive.

Recs

0
Member Avatar pchop12316 (91.74) Submitted: 4/19/2018 11:41:11 AM : Underperform Start Price: $2.03 VTVT Score: +21.29

solid underperform

Recs

1
Member Avatar TSIF (99.97) Submitted: 4/18/2018 2:19:10 PM : Underperform Start Price: $2.20 VTVT Score: +26.60

Lead drug stopped. Has others in pipe, but bleeding $4 to $6M a quarter and cash position dwindling with high AP. Highly compensated leadership.
Two phase II for Diabetes will require partnership and funding.
Over $150M net negative.
The $10M from sale of its building may be the catalyst for the 100% spike off the selloff bottom, but will rapidly be soaked up in AP and now they need "rent".

Target Sub $1.50

Cancelled:
The STEADFAST study, two independent and identical randomized, double-blind, placebo-controlled Phase 3 trials (Part A and Part B), was designed to investigate the safety and efficacy of azeliragon as a potential treatment for patients with mild Alzheimer’s disease. The 18-month study targeted enrollment of 800 patients (400 in each trial)

Leaderboard

Find the members with the highest scoring picks in VTVT.

Score Leader

TheTork

TheTork (59.28) Score: +201.52

The Score Leader is the player with the highest score across all their picks in VTVT.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
TSIF 99.97 4/18/2018 Underperform 3M $2.20 -29.09% -2.49% +26.60 1 Comment
gopublic 98.97 4/20/2018 Underperform 5Y $2.16 -27.78% -1.93% +25.85 0 Comment
CMFBLSH 81.43 4/20/2018 Underperform 5Y $2.16 -27.78% -1.93% +25.85 0 Comment
SmartAce 99.96 4/19/2018 Underperform 5Y $2.09 -25.36% -1.65% +23.71 1 Comment
TheGreatSatan 99.99 4/24/2018 Underperform 5Y $2.03 -23.15% -1.53% +21.62 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. pchop12316 91.74 4/19/2018 Underperform 5Y $2.03 -23.20% -1.91% +21.29 1 Comment
gpierson128 96.65 4/23/2018 Underperform 5Y $1.99 -21.63% -0.87% +20.76 0 Comment
80brown 99.96 4/24/2018 Underperform 5Y $1.93 -19.36% -1.14% +18.22 0 Comment
PAGEBOY54 95.10 4/24/2018 Underperform 3W $1.92 -18.72% -1.11% +17.62 0 Comment
BigShort 98.56 4/19/2018 Underperform 3W $1.94 -19.59% -2.05% +17.54 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for VTVT.

Featured Broker Partners